Logo

Everest Licensing Partner Venatorx Report Results of Cefepime-Taniborbactam in P-III (CERTAIN-1) Study for Complicated Urinary Tract Infections

Share this
Everest Licensing Partner Venatorx Report Results of Cefepime-Taniborbactam in P-III (CERTAIN-1) Study for Complicated Urinary Tract Infections

Everest Licensing Partner Venatorx Report Results of Cefepime-Taniborbactam in P-III (CERTAIN-1) Study for Complicated Urinary Tract Infections

Shots:

  • The P-III (CERTAIN-1) study evaluates cefepime-taniborbactam vs meropenem in a ratio (2:1) in 661 patients with cUTI including acute pyelonephritis
  • The trial met its 1EPs of non-inferiority (NI) in microITT population at TOC ( 70.0% vs 58.0%). A prespecified test showed the superiority of cefepime-taniborbactam for the composite EPs at TOC & was sustained in the composite microbiologic & clinical response at late-follow-pp (Day 28-35) visit
  • Serious TEAEs (2.0% vs 1.8%), treatment discontinuations due to TEAEs (3.0% vs 0.9%). Under an exclusive licensing agreement with Venatorx, Everest gets the rights to develop & commercialize the product in Mainland China & 10 other countries

Ref: PR Newswire | Image: Everest Medicines

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions